The Clinical Application of Peripheral Embolization Coil Systems in Arteriovenous Embolization Within the Peripheral Vasculature

Inclusion Criteria: 1. Aged 18 to 75 years (inclusive), regardless of gender; 2. Patients diagnosed preoperatively via imaging (including but not limited to ultrasound, CTA, MRA, DSA, etc.) with peripheral arteriovenous conditions requiring embolization therapy; 3. The visually estimated normal reference diameter of the target vessel is ≥ 3mm; 4. Patients or their legally authorized representatives are capable of understanding the study objectives, voluntarily participating in this study, providing signed informed consent, and able to comply with follow-up. Exclusion Criteria: 1. The target vessel requires the concurrent use of other embolic materials (e.g., Gelfoam, embolic microspheres, liquid embolic agents, etc.); 2. Known definite history of allergy to platinum, tungsten metals, and/or any component of the investigational product; 3. Subjects with pre-existing severe cardiac, hepatic, renal, respiratory diseases, or coagulation disorders who are unsuitable for anesthesia or endovascular surgical treatment; 4. High-flow arteriovenous fistulas that may cause migration of the embolic material; 5. The target aneurysm is a blister aneurysm, dissecting aneurysm, mycotic (infectious) aneurysm, ruptured aneurysm, or aneurysm caused by connective tissue diseases; 6. Severe vascular stenosis or tortuosity, or anatomical anomalies where it is anticipated that the device will be difficult to navigate to the lesion site, or other uncommon anatomies that may interfere with device use; 7. The target vessel has undergone any previous embolization therapy or surgical intervention, or has recurrent disease; 8. Definite allergy, resistance, or contraindication to antiplatelet drugs, anticoagulants, contrast media, and/or anesthetics; 9. Females who are pregnant, breastfeeding, or planning to become pregnant within 6 months; males planning for parenthood within the next 6 months; 10. Subjects currently participating in other drug or device clinical trials who have not reached the trial endpoint; 11. Investigators deem the subject unsuitable for participation in this study.